OncoPharm cover image

Clinical Trial Endpoints in Oncology

OncoPharm

00:00

When to Use Overall Survival

John Bazar discusses assessing curable versus metastatic disease and when median or landmark overall survival is appropriate.

Play episode from 02:31
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app